RecruitingPhase 2NCT06730126
Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients
Studying OBSOLETE: Lymphoproliferative syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- V. Koneti Rao, M.D.National Institute of Allergy and Infectious Diseases (NIAID)
- Intervention
- Soquelitinib(drug)
- Enrollment
- 15 enrolled
- Eligibility
- 16-120 years · All sexes
- Timeline
- 2025 – 2026
Study locations (3)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
- The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Texas Children's Hospital, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06730126 on ClinicalTrials.govOther trials for OBSOLETE: Lymphoproliferative syndrome
Additional recruiting or active studies for the same condition.